Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) (NF-kappaB)

Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) is a critical family of inducible transcription factors that serves as a central regulator of innate and adaptive immunity, inflammation, and cell survival [1][8]. In most resting cells, NF-kappaB exists as a heterodimeric complex sequestered in the cytoplasm by inhibitory IkappaB proteins [2][20]. Upon activation by stimuli such as pathogens, cytokines, or cellular stress, the IkappaB kinase (IKK) complex phosphorylates IkappaB, marking it for proteasomal degradation [1][10]. This release allows NF-kappaB to translocate to the nucleus, where it binds to specific DNA sequences to drive the expression of hundreds of genes involved in immune responses and anti-apoptotic pathways [3][14]. In many diseases, particularly cancer and chronic inflammatory conditions, NF-kappaB is constitutively active, promoting pathological cell proliferation and resistance to apoptosis [13][18]. While it is a highly attractive therapeutic target, the development of systemic NF-kappaB inhibitors is significantly challenged by the target's essential roles in normal host defense and cellular homeostasis [11][13]. Consequently, pharmacological blockade often carries risks of severe immunosuppression and multi-organ toxicity, necessitating the investigation of more specific or localized therapeutic strategies [13][16].

Other names

Nuclear factor-kappa betaNF-kappaBNF-KBNuclear factor-kappa BNFKBNuclear factor of kappa light polypeptide gene enhancer in B-cellsKBF1EBP-1

Drugs target the NF-kappaB pathway through several distinct mechanisms: inhibition of the IκB kinase (IKK) complex to prevent phosphorylation of inhibitory proteins [1][9], the use of proteasome inhibitors to prevent the degradation of IκB and subsequent nuclear translocation of NF-kappaB [1][13], and the use of glucocorticoids which induce IκB alpha expression and directly interfere with NF-kappaB transcriptional activity [2][6]. Additionally, certain agents directly inhibit NF-kappaB DNA-binding or its interaction with co-activators [5][7].